Vertex Pharmaceuticals Inc (VRTX) - Total Assets
Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) holds total assets worth $26.48 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Vertex Pharmaceuticals Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Vertex Pharmaceuticals Inc - Total Assets Trend (1990–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Vertex Pharmaceuticals Inc for net asset value and shareholders' equity analysis.
Vertex Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vertex Pharmaceuticals Inc's total assets of $26.48 Billion consist of 42.9% current assets and 57.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.5% |
| Accounts Receivable | $2.05 Billion | 7.9% |
| Inventory | $1.69 Billion | 6.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $424.20 Million | 1.6% |
| Goodwill | $1.09 Billion | 4.2% |
Asset Composition Trend (1990–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VRTX company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vertex Pharmaceuticals Inc's current assets represent 42.9% of total assets in 2025, a decrease from 50.0% in 1990.
- Cash Position: Cash and equivalents constituted 19.5% of total assets in 2025, down from 47.8% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
Vertex Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Vertex Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Jinyu Bio-Technology Co Ltd
SHG:600201
|
China | CN¥6.54 Billion |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
USA | $104.69 Million |
Vertex Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.02 | 2.65 | 4.61 |
| Quick Ratio | 2.57 | 2.29 | 4.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.85 Billion | $6.23 Billion | $6.62 Billion |
Vertex Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Vertex Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.63 |
| Latest Market Cap to Assets Ratio | 4.22 |
| Asset Growth Rate (YoY) | 16.0% |
| Total Assets | $26.14 Billion |
| Market Capitalization | $110.45 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Vertex Pharmaceuticals Inc's assets at a significant premium (4.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vertex Pharmaceuticals Inc's assets grew by 16.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vertex Pharmaceuticals Inc (1990–2025)
The table below shows the annual total assets of Vertex Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $26.14 Billion | +16.02% |
| 2024-12-31 | $22.53 Billion | -0.87% |
| 2023-12-31 | $22.73 Billion | +25.23% |
| 2022-12-31 | $18.15 Billion | +35.13% |
| 2021-12-31 | $13.43 Billion | +14.30% |
| 2020-12-31 | $11.75 Billion | +41.27% |
| 2019-12-31 | $8.32 Billion | +33.18% |
| 2018-12-31 | $6.25 Billion | +76.14% |
| 2017-12-31 | $3.55 Billion | +22.54% |
| 2016-12-31 | $2.89 Billion | +15.89% |
| 2015-12-31 | $2.50 Billion | +6.88% |
| 2014-12-31 | $2.34 Billion | +0.74% |
| 2013-12-31 | $2.32 Billion | -15.96% |
| 2012-12-31 | $2.76 Billion | +25.18% |
| 2011-12-31 | $2.20 Billion | +27.75% |
| 2010-12-31 | $1.73 Billion | -11.76% |
| 2009-12-31 | $1.96 Billion | +99.44% |
| 2008-12-31 | $980.48 Million | +63.01% |
| 2007-12-31 | $601.48 Million | -34.73% |
| 2006-12-31 | $921.58 Million | +67.87% |
| 2005-12-31 | $549.00 Million | +0.65% |
| 2004-12-31 | $545.45 Million | -24.70% |
| 2003-12-31 | $724.41 Million | -11.19% |
| 2002-12-31 | $815.72 Million | -11.83% |
| 2001-12-31 | $925.13 Million | +19.70% |
| 2000-12-31 | $772.88 Million | +232.56% |
| 1999-12-31 | $232.40 Million | -12.73% |
| 1998-12-31 | $266.30 Million | -9.91% |
| 1997-12-31 | $295.60 Million | +105.99% |
| 1996-12-31 | $143.50 Million | +44.95% |
| 1995-12-31 | $99.00 Million | -14.80% |
| 1994-12-31 | $116.20 Million | +90.49% |
| 1993-12-31 | $61.00 Million | +19.61% |
| 1992-12-31 | $51.00 Million | -10.68% |
| 1991-12-31 | $57.10 Million | +520.65% |
| 1990-12-31 | $9.20 Million | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more